GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic …
WEB3 days ago · GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 13% sales growth and strategic innovations in R&D, contrasted with ...
GSK Announces Positive Topline Data on Co-Administration of …
WEB3 days ago · PHILADELPHIA, September 18, 2024 -- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) when co-administered with SHINGRIX (Zoster Vaccine Recombinant ...
Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK's Respiratory Syncytial Virus Vaccine Given Together With …
WEB2 days ago · Wednesday, GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (Respiratory Syncytial ...
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
WEB1 day ago · GSK’s Vaccine sales declined 2% in the United States in the first half of 2024 mainly due to declining sales of Shingrix. U.S. sales of Shingrix declined 19% in the first half of 2024 due to ...
British drugmaker GSK moves mRNA flu vaccine to late-stage trials
WEBSep 12, 2024 · GLAXF. (Reuters) -British drugmaker GSK announced on Thursday positive results from a mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, and said it would now progress to late-stage clinical development. The data showed that a vaccine candidate produced positive immune responses against both A ...
GSK makes a strong start to 2024 with improving outlook for the …
WEBMay 1, 2024 · Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%) Dividend declared of 15p for …
GSK News
WEBStay updated on the latest news from GSK, a global healthcare company with innovative medicines, vaccines and consumer products.
GSK delivers strong 2023 performance and upgrades growth …
WEBJan 31, 2024 · Broad-based performance drives sales, profits and earnings growth: Total 2023 sales £30.3 billion +5% and +14% ex COVID. Vaccines sales +25%, +24% ex COVID. Shingrix £3.4 billion +17%, Arexvy £1.2 billion.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...